Novartis AG / Xiidra (lifitegrast) from Takeda

Dry Eye Disease

$388M Xiidra 2018 net sales (US)

Disease Overview

Dry eye disease (DED) is a chronic, multifactorial ocular surface disorder driven by inflammation and tear film instability, causing burning, grittiness, blurred vision, and reduced quality of life. It disproportionately affects women and older adults, and rising screen use has expanded incidence into younger populations.

Competitive Landscape

The US prescription dry eye market in 2019 was a duopoly: Allergan's Restasis (cyclosporine 0.05%, approved 2003) and Takeda's Xiidra (lifitegrast 5%, approved 2016) were the only two FDA-approved Rx options, with Xiidra uniquely indicated for both signs and symptoms via LFA-1 antagonism. Xiidra delivered $388M in 2018 net sales versus Restasis at >$1B, but Restasis was facing imminent generic erosion and Mylan launched a generic in early 2022. Pipeline pressure was mounting from Sun Pharma's Cequa (cyclosporine 0.09%, approved Aug 2018), Kala Pharmaceuticals' Eysuvis (loteprednol, later approved 2020), and Novaliq's CyclASol/NOV03. Numerous earlier candidates failed to clear FDA (anakinra, diquafosol, rebamipide, tofacitinib). Novartis was already a major OTC and surgical ophthalmics player but lacked an anti-inflammatory Rx; acquiring Xiidra plugged a portfolio gap behind the now-defunct Alcon spin-off and gave Novartis a launched, growing, branded asset to anchor a front-of-eye franchise. The deal also deleveraged Takeda post-Shire by monetizing a non-core specialty asset. Novartis later sold Xiidra to Bausch + Lomb in 2023 for up to $2.5B after underwhelming sales growth, signaling that the original $5.3B price was rich for the indication's commercial trajectory.